• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner.印度斯坦分枝杆菌和牛分枝杆菌卡介苗以Toll样受体依赖的方式导致不同的巨噬细胞活化。
Immunology. 2014 Oct;143(2):258-68. doi: 10.1111/imm.12306.
2
Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory cytokines by mycobacterial lipomannan.酰化作用决定了分枝杆菌脂甘露聚糖对促炎细胞因子的Toll样受体(TLR)依赖性正向调节与对TLR2、甘露糖受体和信号调节蛋白1(SIGNR1)非依赖性负向调节。
J Biol Chem. 2007 Sep 7;282(36):26014-25. doi: 10.1074/jbc.M702690200. Epub 2007 Jul 6.
3
Mycobacterium indicus pranii therapy induces tumor regression in MyD88- and TLR2-dependent manner.印度分支杆菌疗法以依赖MyD88和TLR2的方式诱导肿瘤消退。
BMC Res Notes. 2019 Oct 7;12(1):648. doi: 10.1186/s13104-019-4679-0.
4
Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans.分枝杆菌脂甘露聚糖对促炎细胞因子的Toll样受体2(TLR2)依赖性正向调节和TLR2非依赖性负向调节
J Immunol. 2004 Apr 1;172(7):4425-34. doi: 10.4049/jimmunol.172.7.4425.
5
Mycobacterium tuberculosis MymA is a TLR2 agonist that activate macrophages and a T1 response.结核分枝杆菌MymA是一种可激活巨噬细胞和T1反应的Toll样受体2(TLR2)激动剂。
Tuberculosis (Edinb). 2017 Sep;106:16-24. doi: 10.1016/j.tube.2017.05.005. Epub 2017 May 26.
6
Mycobacterium indicus pranii mediates macrophage activation through TLR2 and NOD2 in a MyD88 dependent manner.印度分枝杆菌通过 TLR2 和 NOD2 依赖 MyD88 途径介导巨噬细胞激活。
Vaccine. 2012 Aug 24;30(39):5748-54. doi: 10.1016/j.vaccine.2012.07.002. Epub 2012 Jul 13.
7
PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2.PPE57诱导巨噬细胞活化,并通过Toll样受体2(TLR2)驱动1型辅助性T细胞(Th1)免疫反应。
J Mol Med (Berl). 2015 Jun;93(6):645-62. doi: 10.1007/s00109-014-1243-1. Epub 2015 Jan 15.
8
Activation of Toll-like receptors by Burkholderia pseudomallei.类鼻疽伯克霍尔德菌对Toll样受体的激活作用。
BMC Immunol. 2008 Aug 8;9:46. doi: 10.1186/1471-2172-9-46.
9
Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan.同时阻断人类Toll样受体2和4可抑制卡介苗肽聚糖诱导的髓样树突状细胞活化。
Infect Immun. 2003 Aug;71(8):4238-49. doi: 10.1128/IAI.71.8.4238-4249.2003.
10
Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling.印度分支杆菌(MIP)介导的宿主针对结核感染的细胞内保护机制:Toll样受体4(TLR-4)介导的信号传导参与其中。
Tuberculosis (Edinb). 2016 Dec;101:201-209. doi: 10.1016/j.tube.2016.09.027. Epub 2016 Sep 30.

引用本文的文献

1
promising immunotherapeutic intervention for diseases.有希望用于疾病的免疫治疗干预。
Front Immunol. 2024 Oct 29;15:1450118. doi: 10.3389/fimmu.2024.1450118. eCollection 2024.
2
The Role of Mycobacterium indicus pranii in Sepsis Management: A Comprehensive Review of Clinical Outcomes and Therapeutic Potential.印度斯坦分枝杆菌在脓毒症管理中的作用:临床结局与治疗潜力的全面综述
Cureus. 2024 Aug 13;16(8):e66772. doi: 10.7759/cureus.66772. eCollection 2024 Aug.
3
(MIP) Vaccine: Pharmacology, Indication, Dosing Schedules, Administration, and Side Effects in Clinical Practice.(MIP)疫苗:临床实践中的药理学、适应症、给药方案、接种方法及副作用
Indian Dermatol Online J. 2023 Oct 17;14(6):753-761. doi: 10.4103/idoj.idoj_360_23. eCollection 2023 Nov-Dec.
4
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.肿瘤相关巨噬细胞作为甲状腺癌潜在的治疗靶点。
Cancer Immunol Immunother. 2023 Dec;72(12):3895-3917. doi: 10.1007/s00262-023-03549-6. Epub 2023 Oct 5.
5
Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.膀胱癌患者膀胱内注射卡介苗会引发针对 SARS-CoV-2 的固有免疫应答。
Front Immunol. 2023 Jul 13;14:1202157. doi: 10.3389/fimmu.2023.1202157. eCollection 2023.
6
Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.破解实体瘤的免疫反应:利用溶瘤细菌的抗癌能力
Pharmaceutics. 2023 Jul 21;15(7):2004. doi: 10.3390/pharmaceutics15072004.
7
Augmenting Vaccine Efficacy against Delta Variant with 'Mycobacterium-'-Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways.通过“分枝杆菌”介导的自然杀伤细胞抗体依赖的细胞介导的细胞毒性及Toll样受体-髓样分化因子88信号通路调节增强疫苗对德尔塔变异株的效力
Vaccines (Basel). 2023 Feb 1;11(2):328. doi: 10.3390/vaccines11020328.
8
Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections.BCG 膀胱内灌注治疗非肌层浸润性膀胱癌可诱导获得性免疫,降低呼吸道感染风险。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005518.
9
Cytokine Storm and Immunomodulation in COVID-19.新型冠状病毒肺炎中的细胞因子风暴与免疫调节
Indian J Crit Care Med. 2021 Nov;25(11):1288-1291. doi: 10.5005/jp-journals-10071-24029.
10
The role of HIF-1α in BCG-stimulated macrophages polarization and their tumoricidal effects in vitro.HIF-1α 在 BCG 刺激的巨噬细胞极化中的作用及其体外的杀瘤效应。
Med Microbiol Immunol. 2021 Jun;210(2-3):149-156. doi: 10.1007/s00430-021-00708-3. Epub 2021 May 11.

本文引用的文献

1
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.抗 CD47 抗体介导的巨噬细胞吞噬癌细胞可引发有效的抗肿瘤 T 细胞反应。
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. doi: 10.1073/pnas.1305569110. Epub 2013 May 20.
2
M1 and M2 Macrophages: Oracles of Health and Disease.M1和M2巨噬细胞:健康与疾病的预言者
Crit Rev Immunol. 2012;32(6):463-88. doi: 10.1615/critrevimmunol.v32.i6.10.
3
Massive gene acquisitions in Mycobacterium indicus pranii provide a perspective on mycobacterial evolution.印度分枝杆菌大量基因获得为分枝杆菌进化提供了新视角。
Nucleic Acids Res. 2012 Nov;40(21):10832-50. doi: 10.1093/nar/gks793. Epub 2012 Sep 10.
4
Mycobacterium indicus pranii (Mw)-mediated protection against visceral leishmaniasis: involvement of TLR4 signalling.印度分枝杆菌(Mw)介导的内脏利什曼病防护作用:TLR4 信号通路的参与。
J Antimicrob Chemother. 2012 Dec;67(12):2892-902. doi: 10.1093/jac/dks315. Epub 2012 Aug 9.
5
Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model.印度分枝杆菌预防结核的保护效力及其在豚鼠模型中的局部肺部免疫应答。
Vaccine. 2012 Sep 21;30(43):6198-209. doi: 10.1016/j.vaccine.2012.07.061. Epub 2012 Aug 4.
6
Toll-like signaling and the cytokine IL-6 regulate histone deacetylase dependent neuronal survival.Toll 样信号转导和细胞因子 IL-6 调节组蛋白去乙酰化酶依赖的神经元存活。
PLoS One. 2012;7(7):e41033. doi: 10.1371/journal.pone.0041033. Epub 2012 Jul 27.
7
Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis.印度分枝杆菌(Mycobacterium indicus pranii)作为单独或辅助免疫治疗在实验性动物结核病中的应用。
Indian J Med Res. 2011 Nov;134(5):696-703. doi: 10.4103/0971-5916.90999.
8
Protective and pathogenic functions of macrophage subsets.巨噬细胞亚群的保护和致病功能。
Nat Rev Immunol. 2011 Oct 14;11(11):723-37. doi: 10.1038/nri3073.
9
Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice.结核分枝杆菌(MIP)治疗荷瘤小鼠诱导抗肿瘤免疫应答和减少调节性 T 细胞。
PLoS One. 2011;6(9):e25424. doi: 10.1371/journal.pone.0025424. Epub 2011 Sep 30.
10
Mycobacterium indicus pranii is a potent immunomodulator for a recombinant vaccine against human chorionic gonadotropin.印度分枝杆菌是一种针对人绒毛膜促性腺激素的重组疫苗的有效免疫调节剂。
J Reprod Immunol. 2011 Sep;91(1-2):24-30. doi: 10.1016/j.jri.2011.06.099. Epub 2011 Aug 31.

印度斯坦分枝杆菌和牛分枝杆菌卡介苗以Toll样受体依赖的方式导致不同的巨噬细胞活化。

Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner.

作者信息

Kumar Pawan, Tyagi Rohit, Das Gobardhan, Bhaskar Sangeeta

机构信息

National Institute of Immunology, New Delhi, India.

出版信息

Immunology. 2014 Oct;143(2):258-68. doi: 10.1111/imm.12306.

DOI:10.1111/imm.12306
PMID:24766519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4172141/
Abstract

Mycobacterium indicus pranii (MIP) is an atypical mycobacterial species possessing strong immunomodulatory properties. It is a potent vaccine candidate against tuberculosis, promotes Th1 immune response and protects mice from tumours. In previous studies, we demonstrated higher protective efficacy of MIP against experimental tuberculosis as compared with bacillus Calmette-Guérin (BCG). Since macrophages play an important role in the pathology of mycobacterial diseases and cancer, in the present study, we evaluated the MIP in live and killed form for macrophage activation potential, compared it with BCG and investigated the underlying mechanisms. High levels of tumour necrosis factor-α, interleukin-12p40 (IL-12p40), IL-6 and nitric oxide were produced by MIP-stimulated macrophages as compared with BCG-stimulated macrophages. Prominent up-regulation of co-stimulatory molecules CD40, CD80 and CD86 was also observed in response to MIP. Loss of response in MyD88-deficient macrophages showed that both MIP and BCG activate the macrophages in a MyD88-dependent manner. MyD88 signalling pathway culminates in nuclear factor-κB/activator protein-1 (NF-κB/AP-1) activation and higher activation of NF-κB/AP-1 was observed in response to MIP. With the help of pharmacological inhibitors and Toll-like receptor (TLR) -deficient macrophages, we observed the role of TLR2, TLR4 and intracellular TLRs in MIP-mediated macrophage activation. Stimulation of HEK293 cells expressing TLR2 in homodimeric or heterodimeric form showed that MIP has a distinctly higher level of TLR2 agonist activity compared with BCG. Further experiments suggested that TLR2 ligands are well exposed in MIP whereas they are obscured in BCG. Our findings establish the higher macrophage activation potential of MIP compared with BCG and delineate the underlying mechanism.

摘要

印度斯坦分枝杆菌(MIP)是一种具有强大免疫调节特性的非典型分枝杆菌物种。它是一种抗结核病的有力疫苗候选物,可促进Th1免疫反应并保护小鼠免受肿瘤侵害。在先前的研究中,我们证明与卡介苗(BCG)相比,MIP对实验性结核病具有更高的保护效力。由于巨噬细胞在分枝杆菌疾病和癌症的病理过程中起重要作用,因此在本研究中,我们评估了活的和灭活形式的MIP对巨噬细胞的激活潜力,将其与BCG进行比较并研究其潜在机制。与BCG刺激的巨噬细胞相比,MIP刺激的巨噬细胞产生了高水平的肿瘤坏死因子-α、白细胞介素-12p40(IL-12p40)、IL-6和一氧化氮。在对MIP的反应中,还观察到共刺激分子CD40、CD80和CD86的显著上调。MyD88缺陷型巨噬细胞反应丧失表明,MIP和BCG均以MyD88依赖性方式激活巨噬细胞。MyD88信号通路最终导致核因子-κB/激活蛋白-1(NF-κB/AP-1)激活,并且在对MIP的反应中观察到NF-κB/AP-1的更高激活。借助药理学抑制剂和Toll样受体(TLR)缺陷型巨噬细胞,我们观察到TLR2、TLR4和细胞内TLR在MIP介导的巨噬细胞激活中的作用。刺激以同型二聚体或异型二聚体形式表达TLR2的HEK293细胞表明,与BCG相比,MIP具有明显更高水平的TLR2激动剂活性。进一步的实验表明,TLR2配体在MIP中暴露良好,而在BCG中则被掩盖。我们的研究结果证实了MIP与BCG相比具有更高的巨噬细胞激活潜力,并阐明了其潜在机制。